Key Takeaways
- Strong demand, Europe+1 tailwind: Consolidated revenue grew 55% YoY as multinationals accelerated sourcing shifts from Europe to India, a trend management expects will add 20–25 niche products in the near term.
- Margins held despite cost headwinds: Profit margins were maintained through high crude prices and inflation, supported by a transparent cost-plus model with multinational customers and niche, complex chemistry.
- CapEx cycle is scaling up: A ₹670 crores CapEx program over 18–24 months was announced, targeting fluorination and new products, with management targeting a minimum 1.75x asset turnover on the deployed capital.
- Working capital is improving: Inventory days fell from 296 to 273, operating cash flow of ₹97 crores for H1 exceeded PAT, and management is targeting a return toward historical inventory levels by year-end.
- What to watch next quarter: The pace of new product signings under the Europe+1 strategy, the commissioning timeline for the expanded CapEx, and whether working capital compression continues toward the year-end target.
Demand Environment & Europe+1 Strategy
- Europe+1 is accelerating: Multinational customers, particularly in Europe, are shifting sourcing to India with added urgency. Products previously manufactured in Europe are now being sourced exclusively from Anupam, and some products originally planned for 2025 will launch in 2023.
- Cost differential is structural: Sulphuric acid prices in India are one-fourth of European levels, creating a durable cost advantage that management frames as a long-term shift, not a knee-jerk reaction to temporary price spikes.
- Customer pipeline broadening: Strong interest is coming from all major current customers plus potential new ones. Two new LOIs were signed after the quarter-end with revenue potential of around $10 million.
- Product portfolio expanding: One new product was commercialized during the quarter, taking the total to 49. The company onboarded one of the largest specialty chemical companies in North America, bringing multinational customers to 27.
Anand Desai: "This has been in the works since last 1.5 years to 2 years. But with the Europe-plus-one situation, this has got an added urgency from the customer side now."
CapEx Program & Capacity Expansion
- ₹670 crores over 18–24 months: The total CapEx includes the ₹250 crores previously guided for LOIs and contracts, with the balance directed toward new products and additional demand. FY23 CapEx is pegged at around ₹250 crores, with FY24 at ₹350–400 crores.
- Fluorination is the focus: 14 new fluorination molecules have been identified, and new multipurpose plants will lean more toward fluorination chemistry. Revenue potential from fluorination is ₹220–260 crores at full potential over a longer period.
- Ramp-up timeline: All CapEx will be commissioned within 24 months, with full ramp-up to the 1.75x asset turnover target expected in two to two-and-a-half years from commissioning, implying a ~4–4.5 year horizon as assets come on stream sequentially.
- Current assets still delivering: Existing assets, currently at 1–1.1x asset turn, are expected to deliver growth for the next 18–24 months and should reach a similar asset turnover.
- Margins on new molecules: Expected to be similar to current margins, possibly better, though management guides conservatively to assume similar margins for now.
Vishal Thakkar: "They should be better, but let's look at similar margins for now and then we can see as we go."
Working Capital & Cash Flow
- Inventory days improving: Inventory days reduced from 296 to 273, driven by revising contract pricing mechanisms to six-month cycles and reducing cautionary inventory held for customers.
- Operating cash flow healthy: OCF of ₹97 crores for H1 FY23 exceeded PAT, and management expects continued improvement in operating cash flows and return ratios.
- Year-end target: Management is endeavoring to move back toward historical inventory levels by year-end, with further compression targeted going forward.
- Contract structure tightening: Newer contracts will follow structures similar to existing business, but management will keep tightening toward shorter cycles while maintaining a responsible single/primary supplier role.
- No significant external financing needed: Operating cash flows are expected to suffice for working capital requirements for growth, and combined with working capital compression, no significant external financing is anticipated.
Customer & Revenue Profile
- Revenue growth: Standalone revenue grew 25% YoY, consolidated revenue grew 55% YoY, driven by robust demand and strong client relationships.
- Geographic mix: Europe contributed 35% of revenue, India 31%, Japan 15%, with exports at 69% of total revenue.
- Customer concentration: Top 10 customers contributed 83% of total revenue across 24 products, reflecting deep, multi-product relationships with large multinationals.
- Long-term contract preference: Anupam prefers long-term agreement products only, and even without written contracts, there must be an understanding based on relationships.
- Pricing philosophy: Management emphasized that Anupam is known as a fair supplier that does not take advantage of manufacturer issues in Europe, prioritizing customer benefit for longer-term payoff.
Anand Desai: "Anupam has been known to be a fair supplier, we do not take advantage of any manufacturer issues in Europe or anywhere else. We have always tried to see our customer benefits, not our benefit because that is what pays off in the longer term."
Tanfac Consolidation & Financial Mechanics
- Consolidation began 21st May 2022: Tanfac is consolidated line-by-line at 100%, with minority interest (74%) shown post-PAT. For FY22, Tanfac numbers were not consolidated, so YoY comparisons are not like-for-like.
- Elimination adjustment: An elimination of ₹1.8 crores (₹1.4 crores dividend plus ₹0.4 crores intercompany profit) was made, which is why consolidated Tanfac profit appears as ~₹6 crores rather than the standalone ₹8.8 crores.
- QIP completed: Fundraising of ₹500 crores through qualified institutional placement was completed with a very positive response, adding long-term marquee investors.
Fire Incident
- Incident details: On 10 September, a fire broke out in one of four units at gate no. 6 in Sachin GIDC. It was brought under control within an hour. Six fatalities were reported, and 18 employees were injured and subsequently discharged. The cause remains under investigation.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| CapEx completion | ₹670 crores total program | 18–24 months from now |
| CapEx ramp-up to target asset turn | 1.75x minimum asset turnover on new capital | 2–2.5 years from commissioning (~4–4.5 years total) |
| Working capital | Return toward historical inventory levels | By year-end |
| FY23 CapEx | Around ₹250 crores | FY23 |
| FY24 CapEx | Around ₹350–400 crores (to be refined) | FY24, with more clarity next quarter |
| ROCE target | 20%-plus | Ongoing |
| New products from Europe+1 | 20–25 niche products added to portfolio | Near term |
| Fluorination revenue potential | ₹220–260 crores at full potential | Longer period |
Key Metrics
| Metric | Q2 FY23 |
|---|---|
| Standalone operating revenue | ₹310.7 cr, up 25% YoY from ₹248.9 cr |
| Consolidated operating revenue | ₹386.2 cr, up 55% YoY from ₹248.9 cr |
| Standalone EBITDA | ₹89.8 cr, up 29% YoY from ₹69.7 cr |
| Standalone EBITDA margin | 29% |
| Consolidated EBITDA | ₹101.2 cr, up 44% YoY from ₹70.2 cr |
| Consolidated PAT | ₹47.8 cr, up 33% YoY from ₹36.1 cr |
| Life science segment revenue | ₹277 cr, 90% of total revenue |
| Exports share | 69% of revenue |
| Revenue from top 10 customers | 83% of total revenue, across 24 products |
| Total products commercialized | 49, one new product added during the quarter |
| Total multinational customers | 27, one new North American customer onboarded |
| Inventory days | 273 days, reduced from 296 days |
| Operating cash flow (H1 FY23) | ₹97 cr, higher than PAT for the period |
| LOIs and contracts signed | ₹2,620 cr |
| Planned CapEx | ₹670 cr approximately, to be deployed over 18–24 months |
| FY23 CapEx guidance | ~₹250 cr |
| FY24 CapEx guidance | ~₹350–400 cr |
| Incremental asset turnover expected | 1.75x |
| Incremental ROCE expected | 20%+ |
| Contracted revenues on six-monthly pricing | 60–70% |
| Fundraising via QIP | ₹500 cr completed |
| Cash balance | ₹192 cr |